Literature DB >> 21626032

Camouflage and sabotage: tumor escape from the immune system.

Isabel Poschke1, Dimitrios Mougiakakos, Rolf Kiessling.   

Abstract

The field of tumor immunology has made great progress in understanding tumor immune interactions. As a consequence a number of immuno-therapeutic approaches have been successfully introduced into the clinic and a large number of promising therapeutic strategies are investigated in ongoing clinical trials. Evaluation of anti-tumor immunity in such trials as well as in animal models has shown that tumor escape from immune recognition and tumor-mediated suppression of anti-tumor immunity can pose a significant obstacle to successful cancer therapy. Here, we review mechanisms of tumor immune escape and immune-subversion with a focus on the research interests in our laboratory: loss of MHC class I on tumor cells, increased oxidative stress, recruitment of myeloid-derived suppressor cells, and regulatory T cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21626032     DOI: 10.1007/s00262-011-1012-8

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  63 in total

Review 1.  Vaccines versus immunotherapy: overview of approaches in deciding between options.

Authors:  Angus G Dalgleish
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck.

Authors:  Kazuaki Chikamatsu; Koichi Sakakura; Minoru Toyoda; Katsumasa Takahashi; Takanori Yamamoto; Keisuke Masuyama
Journal:  Cancer Sci       Date:  2012-04-11       Impact factor: 6.716

3.  Systemic DNA damage accumulation under in vivo tumor growth can be inhibited by the antioxidant Tempol.

Authors:  Alexandros G Georgakilas; Christophe E Redon; Nicholas F Ferguson; Thomas B Kryston; Palak Parekh; Jennifer S Dickey; Asako J Nakamura; James B Mitchell; William M Bonner; Olga A Martin
Journal:  Cancer Lett       Date:  2014-07-25       Impact factor: 8.679

Review 4.  Optimizing tumor immune response through combination of radiation and immunotherapy.

Authors:  Alissar El Chediak; Ali Shamseddine; Larry Bodgi; Jean-Pierre Obeid; Fady Geara; Youssef H Zeidan
Journal:  Med Oncol       Date:  2017-08-21       Impact factor: 3.064

5.  Regulatory T cell subsets in patients with medulloblastoma at diagnosis and during standard irradiation and chemotherapy (PBTC N-11).

Authors:  Sridharan Gururangan; Elizabeth Reap; Robert Schmittling; Mehmet Kocak; Renee Reynolds; Gerald Grant; Arzu Onar-Thomas; Patricia Baxter; Ian F Pollack; Peter Phillips; James Boyett; Maryam Fouladi; Duane Mitchell
Journal:  Cancer Immunol Immunother       Date:  2017-08-20       Impact factor: 6.968

6.  Exosomal TGF-β1 is correlated with lymphatic metastasis of gastric cancers.

Authors:  Er-Yen Yen; Shi-Chuen Miaw; Jhang-Sian Yu; I-Rue Lai
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

7.  Suppressive effects of tumor cell-derived 5'-deoxy-5'-methylthioadenosine on human T cells.

Authors:  Frederik C Henrich; Katrin Singer; Kerstin Poller; Luise Bernhardt; Carolin D Strobl; Katharina Limm; Axel P Ritter; Eva Gottfried; Simon Völkl; Benedikt Jacobs; Katrin Peter; Dimitrios Mougiakakos; Katja Dettmer; Peter J Oefner; Anja-Katrin Bosserhoff; Marina P Kreutz; Michael Aigner; Andreas Mackensen
Journal:  Oncoimmunology       Date:  2016-06-10       Impact factor: 8.110

8.  Exosomes from myeloid-derived suppressor cells carry biologically active proteins.

Authors:  Meghan Burke; Waeowalee Choksawangkarn; Nathan Edwards; Suzanne Ostrand-Rosenberg; Catherine Fenselau
Journal:  J Proteome Res       Date:  2013-12-13       Impact factor: 4.466

Review 9.  Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.

Authors:  Elizabeth Buchbinder; F Stephen Hodi
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

10.  [Lung cancer. Molecular pathology and personalized therapy].

Authors:  A Schultheis; J Wolf; R Büttner
Journal:  Internist (Berl)       Date:  2013-02       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.